Catalyst Pharmaceuticals, Inc. cash flow to debt ratio of 7.49K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Catalyst Pharmaceuticals, Inc.'s free cash flow has decreased -12.81% from $239.25M last year to $208.61M, signaling decreasing performance

Catalyst Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Catalyst Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Catalyst Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Catalyst Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Catalyst Pharmaceuticals, Inc.'s profit margin has increased (11.24%) in the last year from 33.33% to 37.08%, signaling increasing performance

Catalyst Pharmaceuticals, Inc.'s short-term assets of $894.03M exceed its short-term liabilities of $147.15M

Catalyst Pharmaceuticals, Inc.'s return on assets of 19.29% is higher than the 5.00% threshold, indicating efficient asset utilization

Catalyst Pharmaceuticals, Inc.'s return on equity of 23.65%, is higher than 15.00%, indicating good performance

Catalyst Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Catalyst Pharmaceuticals, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Catalyst Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Catalyst Pharmaceuticals, Inc. has a free cash flow yield of 5.41%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Catalyst Pharmaceuticals, Inc.'s yearly earnings has increased 30.78% since last year from $163.89M to $214.33M, signaling increasing performance

Catalyst Pharmaceuticals, Inc.'s yearly revenue has increased 19.78% since last year from $491.73M to $588.99M, signaling increasing performance

ROIC 19.67% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Catalyst Pharmaceuticals, Inc.'s 3-year revenue CAGR of 40.10% is positive, indicating growing revenue over the past 3 years

Catalyst Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Catalyst Pharmaceuticals, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Catalyst Pharmaceuticals, Inc. is undervalued relative to its fair value price of 35.88 based on Discounted Cash Flow model

Catalyst Pharmaceuticals, Inc. has an earnings yield of 5.75%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Catalyst Pharmaceuticals, Inc. is overvalued relative to its fair value price of 24.03 based on EBITDA multiple model

Catalyst Pharmaceuticals, Inc. has an EV/EBITDA ratio of 9.27x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Catalyst Pharmaceuticals, Inc. is undervalued relative to its fair value price of 33.02 based on Earnings Fair Value model

Catalyst Pharmaceuticals, Inc. has a PEG-ratio over 1 which is considered overvalued

Catalyst Pharmaceuticals, Inc. has a price-to-book ratio of 3.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Catalyst Pharmaceuticals, Inc. has a price-to-sales ratio of 6.46x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue